Kriya Therapeutics raised $313 million to advance gene therapies across ophthalmic, metabolic, and neurological diseases, continuing robust investment in chronic disease treatment. LB Pharmaceuticals is preparing an IPO amid Phase III antipsychotic developments, reflecting sustained capital interest despite sector challenges.